Wang X - Search Results

1

PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.

Gupta P, Kathawala RJ, Wei L, Wang F, Wang X, Druker BJ, Fu LW, Chen ZS. Gupta P, et al. Among authors: wang x, wang f. Cancer Lett. 2016 Dec 28;383(2):220-229. doi: 10.1016/j.canlet.2016.09.025. Epub 2016 Oct 5. Cancer Lett. 2016. PMID: 27720778

2

Interaction of tyrosine kinase inhibitors with the MDR- related ABC transporter proteins.

Wang XK, Fu LW. Wang XK, et al. Curr Drug Metab. 2010 Sep;11(7):618-28. doi: 10.2174/138920010792927316. Curr Drug Metab. 2010. PMID: 20812904 Review.

3

A cell-based screen for anticancer activity of 13 pyrazolone derivatives.

Wang XH, Wang XK, Liang YJ, Shi Z, Zhang JY, Chen LM, Fu LW. Wang XH, et al. Chin J Cancer. 2010 Dec;29(12):980-7. doi: 10.5732/cjc.010.10309. Chin J Cancer. 2010. PMID: 21114917 Free article.

4

Structure identification of Euphorbia factor L3 and its induction of apoptosis through the mitochondrial pathway.

Zhang JY, Liang YJ, Chen HB, Zheng LS, Mi YJ, Wang F, Zhao XQ, Wang XK, Zhang H, Fu LW. Zhang JY, et al. Molecules. 2011 Apr 15;16(4):3222-31. doi: 10.3390/molecules16043222. Molecules. 2011. PMID: 21499222 Free PMC article.

5

Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein.

Zhou WJ, Zhang X, Cheng C, Wang F, Wang XK, Liang YJ, To KK, Zhou W, Huang HB, Fu LW. Zhou WJ, et al. Among authors: wang f, wang xk. Br J Pharmacol. 2012 Jul;166(5):1669-83. doi: 10.1111/j.1476-5381.2012.01849.x. Br J Pharmacol. 2012. PMID: 22233293 Free PMC article.

6

FG020326 sensitized multidrug resistant cancer cells to docetaxel-mediated apoptosis via enhancement of caspases activation.

Wang XW, Wang XK, Zhang X, Liang YJ, Shi Z, Chen LM, Fu LW. Wang XW, et al. Among authors: wang xk. Molecules. 2012 May 9;17(5):5442-58. doi: 10.3390/molecules17055442. Molecules. 2012. PMID: 22572929 Free PMC article.

7

BIRB796, the inhibitor of p38 mitogen-activated protein kinase, enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cells.

He D, Zhao XQ, Chen XG, Fang Y, Singh S, Talele TT, Qiu HJ, Liang YJ, Wang XK, Zhang GQ, Chen ZS, Fu LW. He D, et al. PLoS One. 2013;8(1):e54181. doi: 10.1371/journal.pone.0054181. Epub 2013 Jan 18. PLoS One. 2013. PMID: 23349819 Free PMC article.

8

Nilotinib enhances the efficacy of conventional chemotherapeutic drugs in CD34⁺CD38⁻ stem cells and ABC transporter overexpressing leukemia cells.

Wang F, Wang XK, Shi CJ, Zhang H, Hu YP, Chen YF, Fu LW. Wang F, et al. Molecules. 2014 Mar 19;19(3):3356-75. doi: 10.3390/molecules19033356. Molecules. 2014. PMID: 24651611 Free PMC article.

9

Afatinib enhances the efficacy of conventional chemotherapeutic agents by eradicating cancer stem-like cells.

Wang XK, He JH, Xu JH, Ye S, Wang F, Zhang H, Huang ZC, To KK, Fu LW. Wang XK, et al. Cancer Res. 2014 Aug 15;74(16):4431-45. doi: 10.1158/0008-5472.CAN-13-3553. Epub 2014 Jun 27. Cancer Res. 2014. PMID: 24972892

10

CEP-33779 antagonizes ATP-binding cassette subfamily B member 1 mediated multidrug resistance by inhibiting its transport function.

Tang SJ, Chen LK, Wang F, Zhang YK, Huang ZC, To KK, Wang XK, Talele TT, Chen ZS, Chen WQ, Fu LW. Tang SJ, et al. Biochem Pharmacol. 2014 Sep 15;91(2):144-56. doi: 10.1016/j.bcp.2014.07.008. Epub 2014 Jul 21. Biochem Pharmacol. 2014. PMID: 25058526

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

209,066 results

Search Page

Filters